Document Detail

Relation of Growth-Differentiation Factor 15 to Left Ventricular Remodeling in ST-Segment Elevation Myocardial Infarction.
MedLine Citation:
PMID:  21784389     Owner:  NLM     Status:  Publisher    
The development of left ventricular remodeling (LVR) after myocardial infarction is associated with a high risk of heart failure and death. LVR is difficult to predict, and limited information is available on the association of cardiac biomarkers and LVR. Growth-differentiation factor-15 (GDF-15) is induced during heart failure development and, in animals models, might influence the different processes involved in cardiac remodeling. The aim of the present investigation was to assess the association between the serum levels of GDF-15 within the first 24 hours of ST-segment elevation myocardial infarction and the development of subsequent LVR at 12 months of follow-up. This prospective study included 97 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Echocardiography was performed in all patients within the first 96 hours of admission and at 12 months of follow-up. LVR was defined as a >20% increase in the left ventricular end-diastolic volume at 12 months of follow-up compared to baseline. Blood samples for the determination of GDF-15 and brain natriuretic peptide were obtained within the first 24 hours after symptom onset. According to the pre-established criteria, 21 patients (22%) had LVR. Patients with LVR had greater levels of GDF-15 at study entry (median 3,439 pg/ml, interquartile range 2,391 to 6,168 vs median 1998 pg/ml, interquartile range 1,204 to 3,067, respectively; p <0.001). Multivariate analysis showed that GDF-15 (odds ratio 10.1, 95% confidence interval 2.5 to 40.1, p <0.001) and treatment with angiotensin-converting enzyme inhibitors (odds ratio 3.9, 95% confidence interval 1.2 to 12.3, p <0.01) were independents predictors of LVR. Receiving operating characteristics analysis showed an area under the curve of 0.77 for GDF-15 (95% confidence interval 0.67 to 0.84, p <0.001). In conclusion, the results of the present study have identified GDF-15 as an independent marker of LVR in patients with ST-segment elevation myocardial infarction.
Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez; Pablo Avanzas
Related Documents :
11381289 - Why were the results of the heart outcomes prevention evaluation (hope) trial so astoun...
21958769 - Effect of prior cardiac operations on survival after coronary artery bypass grafting.
21713529 - Evaluation of left ventricular twist in acute myocardial infarction patients using spec...
6142449 - Pirbuterol hydrochloride: evaluation of beta adrenergic agonist activity in reversible ...
10908079 - Electrophysiological changes of angiotensin-converting enzyme inhibition after myocardi...
12681239 - Beta-blockers in chronic heart failure: what have we learned? what do we still need to ...
9602589 - Lidocaine increases the ventricular fibrillation threshold during bupivacaine-induced c...
24123919 - Biomimetic materials design for cardiac tissue regeneration.
17921739 - Clinical trials versus registries in coronary revascularization: which are more relevant?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-22
Journal Detail:
Title:  The American journal of cardiology     Volume:  -     ISSN:  1879-1913     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Department of Cardiology, Hospital Universitario de Canarias, Tenerife, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Outcomes of Coronary Arterial Perforations During Percutaneous Coronary Intervention With Bivalirudi...
Next Document:  Sex Differences in Neointimal Hyperplasia Following Endeavor Zotarolimus-Eluting Stent Implantation.